Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Opens in a new tab or window Higher-potency topical corticosteroids, JAK inhibitors, and tacrolimus 0.1% were deemed the most effective topical anti-inflammatory treatments for atopic dermatitis ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

“Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed ... via LillyPlus will not change as we tenaciously pursue options ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory ...

About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...

(Shutterstock) Understanding Atopic Dermatitis empowers individuals to manage their condition effectively and live more comfortably. With ongoing advancements in treatment options, there is ...